Latest news
ASCO 2026: Are we overtreating cancer?
The biggest oncology story in Chicago was not only who needs more treatment. It was who may safely need less.
Latin America Challenges the Dementia Biomarker Evidence Gap
China’s Alzheimer’s Blood-Test Rollout Turns Diagnosis Into an Access Market
Alzheimer’s Blood Testing Moves Toward Routine Care
AI Mental Health Support Becomes a Governance Test
Alzheimer’s Drugs Force NICE Back Into the Value Debate
Europe Starts Treating Brain Health as System Resilience
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.